Skip to main content

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.

Publication ,  Journal Article
Cosgrove, CA; Lacey, CJ; Cope, AV; Bartolf, A; Morris, G; Yan, C; Baden, S; Cole, T; Carter, D; Brodnicki, E; Shen, X; Joseph, S; DeRosa, SC ...
Published in: PLoS One
2016

BACKGROUND: Defining optimal routes for induction of mucosal immunity represents an important research priority for the HIV-1 vaccine field. In particular, it remains unclear whether mucosal routes of immunization can improve mucosal immune responses. METHODS: In this randomized two center phase I clinical trial we evaluated the systemic and mucosal immune response to a candidate HIV-1 Clade C CN54gp140 envelope glycoprotein vaccine administered by intramuscular (IM), intranasal (IN) and intravaginal (IVAG) routes of administration in HIV negative female volunteers. IM immunizations were co-administered with Glucopyranosyl Lipid Adjuvant (GLA), IN immunizations with 0.5% chitosan and IVAG immunizations were administered in an aqueous gel. RESULTS: Three IM immunizations of CN54 gp140 at either 20 or 100 μg elicited significantly greater systemic and mucosal antibodies than either IN or IVAG immunizations. Following additional intramuscular boosting we observed an anamnestic antibody response in nasally primed subjects. Modest neutralizing responses were detected against closely matched tier 1 clade C virus in the IM groups. Interestingly, the strongest CD4 T-cell responses were detected after IN and not IM immunization. CONCLUSIONS: These data show that parenteral immunization elicits systemic and mucosal antibodies in women. Interestingly IN immunization was an effective prime for IM boost, while IVAG administration had no detectable impact on systemic or mucosal responses despite IM priming. CLINICAL TRIALS REGISTRATION: EudraCT 2010-019103-27 and the UK Clinical Research Network (UKCRN) Number 11679.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2016

Volume

11

Issue

5

Start / End Page

e0152038

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vagina
  • Mucous Membrane
  • Middle Aged
  • Injections, Intramuscular
  • Immunoglobulin G
  • Immunity, Cellular
  • Humans
  • HIV Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cosgrove, C. A., Lacey, C. J., Cope, A. V., Bartolf, A., Morris, G., Yan, C., … Shattock, R. J. (2016). Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PLoS One, 11(5), e0152038. https://doi.org/10.1371/journal.pone.0152038
Cosgrove, Catherine A., Charles J. Lacey, Alethea V. Cope, Angela Bartolf, Georgina Morris, Celine Yan, Susan Baden, et al. “Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.PLoS One 11, no. 5 (2016): e0152038. https://doi.org/10.1371/journal.pone.0152038.
Cosgrove, Catherine A., et al. “Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.PLoS One, vol. 11, no. 5, 2016, p. e0152038. Pubmed, doi:10.1371/journal.pone.0152038.
Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Stöhr W, McCormack S, Shattock RJ. Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PLoS One. 2016;11(5):e0152038.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2016

Volume

11

Issue

5

Start / End Page

e0152038

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vagina
  • Mucous Membrane
  • Middle Aged
  • Injections, Intramuscular
  • Immunoglobulin G
  • Immunity, Cellular
  • Humans
  • HIV Antibodies